PDB4 HbA1C Reduction Associated with Initial Versus Sequential Combination Therapy with Pioglitazone (PIO) and Dipeptidyl Peptidase-4 Inhibitors (dpp4i) in Patients with Type 2 Diabetes Mellitus (T2DM)

M. Bron,K. Chen,R. Ayyagari,H. Sharma,E. Q. Wu

DOI: https://doi.org/10.1016/j.jval.2012.08.1647

IF: 5.156

2012-01-01

Value in Health

Abstract:For the management of T2DM using combination therapy with PIO and DPP4i, there is no consensus on whether to initiate both drugs simultaneously or start with PIO followed by sequential addition of DPP4i. We aimed to assess impact of initial vs. sequential combination therapy with PIO and DPP4i on HbA1C reduction. A chart review was conducted among people with T2DM to examine the effectiveness of sequential vs. initial combination therapy. Selected patients had HbA1C≥7 at initiation of combination therapy (baseline) and no prior insulin or DPP4i use. Initial combination was defined as initiation of PIO and DPP4i within 30 days of each other; sequential combination was defined as having PIO monotherapy for ≥ 2 months and initiation of a DPP4i within 1 year of the initiation of PIO. Baseline characteristics were compared between cohorts using Wilcoxon rank-sum and chi-square tests. HbA1C reduction at months 4, 8, 12, and 16 from baseline was compared using linear models adjusting for demographic variables, baseline HbA1C, diabetes duration, comorbidities, and medications. Patients starting initial (n=250) and sequential (n=211) combination with PIO and DPP4i during 3/1/2010 – 2/28/2011 were identified. Patients in the two cohorts were similar in demographics, disease duration, and most comorbidities; however, patients receiving initial combination therapy had higher average baseline HbA1C (8.6 vs. 8.0; P<0.001), a higher proportion with coronary artery disease (11.6% vs. 6.2%; P=0.043), and lower proportions with hyperlipidemia (56.4% vs. 67.8%; P =0.012) and hypertension (62.4% vs. 72.0%; P =0.029). In adjusted analyses, initial combination therapy was associated with greater reduction in HbA1C at months 12 (0.98 vs. 0.82, P=0.034) and 16 (1.45 vs. 1.24, P=0.048) than sequential combination therapy. Initial combination therapy with PIO and DPP4i demonstrated a significantly greater reduction in HbA1C than sequential combination among patients with poorly controlled blood glucose.